BeOne Medicines (MEX:BGNEN) Cyclically Adjusted Revenue per Share: MXN205.11 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BGNEN BeOne Medicines Ltd MEX:BGNEN
77 GF Score
Price MXN2,858.16
GF Value MXN2,908.95
! 5 Warning Signs
View Full Analysis

What is BeOne Medicines Cyclically Adjusted Revenue per Share?

BeOne Medicines MEX:BGNEN 77 Cyclically Adjusted Revenue per Share is MXN205.11 as of Jun. 2026. GuruFocus rates MEX:BGNEN with a GF Score™ of 77/100 and a GF Value™ of MXN2,908.95. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BeOne Medicines's adjusted revenue per share for the three months ended in Jun. 2026 was MXN256.931. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN205.11 for the trailing ten years ended in Jun. 2026.

During the past 12 months, BeOne Medicines's average Cyclically Adjusted Revenue Growth Rate was 41.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-20), BeOne Medicines's current stock price is MXN2858.16. BeOne Medicines's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN205.11. BeOne Medicines's Cyclically Adjusted PS Ratio of today is 13.93.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BeOne Medicines was 23.60. The lowest was 14.12. And the median was 18.57.


BeOne Medicines  (MEX:BGNEN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BeOne Medicines's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2858.16/205.11
=13.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BeOne Medicines was 23.60. The lowest was 14.12. And the median was 18.57.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BeOne Medicines Cyclically Adjusted Revenue per Share Related Terms


BeOne Medicines Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Cyclically Adjusted Revenue per Share Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 185.07 161.34

BeOne Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 170.97 132.55 161.34 180.27 205.11

MEX:BGNEN vs ALNY, RVMD, RPRX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, BeOne Medicines's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Cyclically Adjusted PS Ratio falls into.


MEX:BGNEN
77GF Score
BeOne Medicines Ltd MEX:BGNEN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BeOne Medicines's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=256.931/108.5600*108.5600
=256.931

Current CPI (Jun. 2026) = 108.5600.

BeOne Medicines Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 99.604 0.000
201612 0.000 99.380 0.000
201703 0.000 100.040 0.000
201706 0.000 100.285 0.000
201709 86.501 100.254 93.668
201712 7.855 100.213 8.509
201803 11.463 100.836 12.341
201806 19.310 101.435 20.666
201809 17.816 101.246 19.103
201812 19.385 100.906 20.855
201903 25.334 101.571 27.077
201906 78.157 102.044 83.148
201909 16.467 101.396 17.631
201912 17.679 101.063 18.990
202003 15.785 101.048 16.959
202006 19.495 100.743 21.008
202009 22.765 100.585 24.570
202012 21.905 100.241 23.723
202103 128.033 100.800 137.890
202106 32.506 101.352 34.818
202109 45.758 101.533 48.925
202112 46.181 101.776 49.259
202203 59.585 103.205 62.677
202206 66.843 104.783 69.253
202209 75.346 104.835 78.023
202212 71.412 104.666 74.069
202303 77.487 106.245 79.176
202306 97.532 106.576 99.348
202309 127.252 106.570 129.629
202312 103.471 106.461 105.511
202403 119.634 107.355 120.977
202406 162.584 107.991 163.441
202409 186.223 107.468 188.115
202412 219.774 107.128 222.712
202503 205.603 107.722 207.202
202506 220.025 108.075 221.012
202509 226.226 107.710 228.011
202512 233.367 107.200 236.328
202603 235.736 108.060 236.827
202606 256.931 108.560 256.931

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN205.11 mean?
BeOne Medicines (MEX:BGNEN) has a Cyclically Adjusted Revenue per Share of MXN205.11 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Cyclically Adjusted Revenue per Share too high?
BeOne Medicines' current Cyclically Adjusted Revenue per Share is MXN205.11. Overall, BeOne Medicines has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Cyclically Adjusted Revenue per Share compare to ALNY and RVMD?
BeOne Medicines' Cyclically Adjusted Revenue per Share of MXN205.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Cyclically Adjusted Revenue per Share is MXN205.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (MEX:BGNEN) has a current Cyclically Adjusted Revenue per Share of MXN205.11. The stock's GF Value™ is MXN2,908.95, compared to a current price of MXN2,858.16 — trading 1.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN205.11. BeOne Medicines' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BeOne Medicines (MEX:BGNEN), the current Cyclically Adjusted Revenue per Share is MXN205.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (MEX:BGNEN) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of MXN2,858.16 is trading 1.7% below its estimated GF Value™ of MXN2,908.95.

Key valuation signals for MEX:BGNEN:

  • Cyclically Adjusted Revenue per Share: MXN205.11
  • GF Value™: MXN2,908.95 vs. price of MXN2,858.16 (1.7% below fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the MEX:BGNEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score

Get the complete analysis for MEX:BGNEN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,858.16
Price
MXN2,908.95
GF Value